メインナビゲーションにスキップ 検索にスキップ メインコンテンツにスキップ

Prognostic significance of p16 expression in high-grade prostate adenocarcinoma

  • Taishi Takahara
  • , Akira Satou
  • , Miho Sugie
  • , Masahito Watanabe
  • , Kent Kanao
  • , Makoto Sumitomo
  • , Toyonori Tsuzuki

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

1   !!Link opens in a new tab 被引用数 (Scopus)

抄録

Management of advanced hormone-naïve prostate cancer (HNPC) is a critical public health issue. Useful prognostic markers are thus needed to select patients who will benefit from recently introduced upfront therapies. p16 expression is an adverse prognostic marker in prostate cancer. The present study aimed to determine whether p16 expression would serve as an adverse prognostic marker in advanced HNPC. A total of 79 patients diagnosed by needle biopsy with adenocarcinoma Gleason score ≥8 between 2010 and 2013 at Aichi Medical University were included in this study. The median patient age was 73 (range 52–87) years. The median follow-up was 62 months (range 2–98). Fourteen patients had p16-positive samples. Fifteen patients died from prostate cancer, 10 of whom were in the p16-positive group. p16 positivity was associated with clinical T stage (P < 0.001), presence of IDC-P (P < 0.001), distant metastasis (P < 0.001) and lymph node metastasis (P < 0.001). These results indicate that p16 expression is associated with adverse prognostic factor of prostate cancer and suggest that p16 expression may provide useful information for treatment planning and identifying suitable candidates for upfront chemotherapy or androgen receptor axis-targeted therapy.

本文言語英語
ページ(範囲)743-751
ページ数9
ジャーナルPathology International
巻70
号10
DOI
出版ステータス出版済み - 01-10-2020

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

  1. SDG 3 - すべての人に健康と福祉を
    SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

  • 病理学および法医学

フィンガープリント

「Prognostic significance of p16 expression in high-grade prostate adenocarcinoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル